Response to paclitaxel and carboplatin in metastatic salivary gland cancer: A case report
Background Malignant tumors of the salivary gland are rare entities that are treated primarily by surgical resection. For patients with recurrent or unresectable disease, options include radiation therapy or chemotherapy; however, responses are few and of short duration. Patients with metastatic dis...
Gespeichert in:
Veröffentlicht in: | Head & neck 2002-04, Vol.24 (4), p.406-410 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Malignant tumors of the salivary gland are rare entities that are treated primarily by surgical resection. For patients with recurrent or unresectable disease, options include radiation therapy or chemotherapy; however, responses are few and of short duration. Patients with metastatic disease have been treated with chemotherapy, but, again, response rates have been low and of short duration.
Methods
A 52‐year‐old man was seen with a mass on his tongue. A biopsy revealed adenocarcinoma of a minor salivary gland. Ten months after surgical resection, neck dissection, and radiation therapy, the patient was found to have metastatic disease to the lung. Chemotherapy was initiated with carboplatin and paclitaxel.
Results
The patient obtained a complete response after six cycles of carboplatin and paclitaxel.
Conclusions
The use of carboplatin and paclitaxel in the setting of metastatic salivary gland cancer is a viable option. © 2002 Wiley Periodicals, Inc. Head Neck 24: 406–410, 2002 |
---|---|
ISSN: | 1043-3074 1097-0347 |
DOI: | 10.1002/hed.10034 |